Evidence map›Paper›PMID 26240353›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.

Marco Santoro, Salah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Joseph A Ludwig, Antonios G Mikos

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 104 citations in OpenAlex.

  1. Review
  2. Exploring bone-tumor interactions through 3DJournal of bone oncology · 2025
    Review
  3. Article
  4. Article
  5. Biomechanical Aspects in Bone Tumor Engineering.Tissue engineering. Part B, Reviews · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Small round cell sarcomas.Nature reviews. Disease primers · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The emerging role of cancer nanotechnology in the panorama of sarcoma.Frontiers in bioengineering and biotechnology · 2022
    Review
  19. Journal of bone oncology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marco SantoroDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77005; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054;
Salah-Eddine Lamhamedi-CherradiDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054;
Brian A MenegazDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054;
Joseph A LudwigDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054; mikos@rice.edu jaludwig@mdanderson.org.
Antonios G MikosDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77005; Department of Bioengineering, Rice University, Houston, TX 77030 mikos@rice.edu jaludwig@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USRice University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Three-dimensional Model of Human Ewing SarcomaR01CA180279 · NCI · RICE UNIVERSITY · PI KASPER, FRED KURTIS, LUDWIG, JOSEPH A · 2014 to 2018
$1.8M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA180279
6 · The paper itself

Abstract

Three-dimensional tumor models accurately describe different aspects of the tumor microenvironment and are readily available for mechanistic studies of tumor biology and for drug screening. Nevertheless, these systems often overlook biomechanical stimulation, another fundamental driver of tumor progression. To address this issue, we cultured Ewing sarcoma (ES) cells on electrospun poly(ε-caprolactone) 3D scaffolds within a flow perfusion bioreactor. Flow-derived shear stress provided a physiologically relevant mechanical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elicited a superadditive release in the presence of exogenous IGF1. This finding is particularly relevant, given the central role of the IGF1/IGF-1 receptor (IGF-1R) pathway in ES tumorigenesis and as a promising clinical target. Additionally, flow perfusion enhanced in a rate-dependent manner the sensitivity of ES cells to IGF-1R inhibitor dalotuzumab (MK-0646) and showed shear stress-dependent resistance to the IGF-1R blockade. This study demonstrates shear stress-dependent ES cell sensitivity to dalotuzumab, highlighting the importance of biomechanical stimulation on ES-acquired drug resistance to IGF-1R inhibition. Furthermore, flow perfusion increased nutrient supply throughout the scaffold, enriching ES culture over static conditions. Our use of a tissue-engineered model, rather than human tumors or xenografts, enabled precise control of the forces experienced by ES cells, and therefore provided at least one explanation for the remarkable antineoplastic effects observed by some ES tumor patients from IGF-1R targeted therapies, in contrast to the lackluster effect observed in cells grown in conventional monolayer culture.

Indexed as

Drug Screening Assays, AntitumorAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomechanical PhenomenaBioreactorsCell SurvivalEquipment DesignFlow CytometryHumansInsulin-Like Growth Factor ILigandsMicroscopy, Electron, ScanningMicroscopy, FluorescencePerfusionReceptor, IGF Type 1Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsdalotuzumabInsulin-Like Growth Factor ILigandsReceptor, IGF Type 1biological therapymechanical stimulationtissue engineeringtumor model

Identifiers

PMID26240353
PMCPMC4547215
OpenAlexW2144642762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.